ArticleYonsei medical journal2005
Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer.
Article in Yonsei medical journal, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer.British journal of cancer · 2011Pooled it
- Drivers of Pancreatic Cancer: Beyond the Big 4.Cancers · 2025Review
- Review
- Expression Profile of KRAS and p16 in Periampullary Cancer.Indian journal of surgical oncology · 2024Article
- Systemic Therapy for Patients With Pancreatic Cancer: Current Approaches and Opportunities for Novel Avenues Toward Precision Medicine.Clinical colorectal cancer · 2023Review
- Current Pathology Model of Pancreatic Cancer.Cancers · 2022Review
- Review
- Biological Hallmarks and New Therapeutic Approaches for the Treatment of PDAC.Life (Basel, Switzerland) · 2021Review
- Prognostic significance of p16 protein in pancreatic ductal adenocarcinoma.Molecular and clinical oncology · 2020Article
- The Loss ofJournal of Cancer · 2019Article
- Evaluation of K-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas.PloS one · 2017Article
- Diagnosis of pancreatic lesions collected by endoscopic ultrasound-guided fine-needle aspiration using next-generation sequencing.Oncology letters · 2016Article
- The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma.Pathology oncology research : POR · 2013Article
- Advances in biomarker research for pancreatic cancer.Current pharmaceutical design · 2012Review
- Ductal adenocarcinoma of the pancreas: Expression of growth factor receptors, oncogenes and suppressor genes, and their relationship to pathological features, staging and survival.Oncology letters · 2011Article
- SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- Prognostic implications of cyclin B1, p34cdc2, p27(Kip1) and p53 expression in gastric cancer.Yonsei medical journal · 2007Article
- Pancreas duodenal homeobox-1 expression and significance in pancreatic cancer.World journal of gastroenterology · 2007Article
- Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer.British journal of cancer · 2006Article
- Raised granzyme B levels are associated with erosions in patients with early rheumatoid factor positive rheumatoid arthritis.Annals of the rheumatic diseases · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a disease with poor prognosis mainly due to low resection rates and late diagnosis. To increase resectability and improve survival rates, a better understanding of pancreatic cancer pathogenesis and more effective screening techniques are required. New methods, such as genetic and molecular alterations, may suggest novel approaches for pancreatic cancer diagnosis and treatment. We immunohistochemically investigated 44 formalin-fixed, paraffin-embedded specimens of pancreatic ductal adenocarcinoma using monoclonal anti-p16 antibodies and monoclonal anti-p53 antibodies. The expressions of p16 and p53 proteins were compared using the Chi-square test with SPSS. Disease-free survival was analyzed using the Kaplan-Meier method, verified by the Log- Rank test. Loss of p16 expression was noted in 20 (45.5%) cases and aberrant p53 protein expression was detected in 14 (31.8%) cases. Loss of p16 expression was associated with a higher incidence of lymph node metastasis (p=0.040) and a more advanced stage (p=0.015), although there was no significant correlation between p16 expression and survival. Aberrant p53 protein expression correlated with histologic grade (p= 0.038). Disease-free survival rate was significantly lower in the aberrant p53 protein positive group compared to the negative group (p=0.029). From our results, we suggest that p53 is not a prognostic factor; however, p16 and p53 genes do play important roles in the progression of pancreatic ductal adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.